Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash from Discontinued Operations (2016 - 2025)

Historic Cash from Discontinued Operations for Dr Reddys Laboratories (RDY) over the last 13 years, with Q2 2025 value amounting to $170.9 million.

  • Dr Reddys Laboratories' Cash from Discontinued Operations rose 6783.48% to $170.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $610.0 million, marking a year-over-year increase of 590.39%. This contributed to the annual value of $279.8 million for FY2018, which is 1283.18% down from last year.
  • As of Q2 2025, Dr Reddys Laboratories' Cash from Discontinued Operations stood at $170.9 million, which was up 6783.48% from $101.8 million recorded in Q2 2024.
  • Over the past 5 years, Dr Reddys Laboratories' Cash from Discontinued Operations peaked at $283.3 million during Q4 2022, and registered a low of -$46.8 million during Q2 2021.
  • For the 5-year period, Dr Reddys Laboratories' Cash from Discontinued Operations averaged around $135.1 million, with its median value being $120.3 million (2023).
  • Over the last 5 years, Dr Reddys Laboratories' Cash from Discontinued Operations had its largest YoY gain of 30009.53% in 2021, and its largest YoY loss of 13258.31% in 2021.
  • Over the past 5 years, Dr Reddys Laboratories' Cash from Discontinued Operations (Quarter) stood at $231.3 million in 2021, then rose by 22.48% to $283.3 million in 2022, then plummeted by 57.52% to $120.3 million in 2023, then dropped by 15.37% to $101.8 million in 2024, then surged by 67.83% to $170.9 million in 2025.
  • Its Cash from Discontinued Operations stands at $170.9 million for Q2 2025, versus $101.8 million for Q2 2024 and $120.3 million for Q4 2023.